{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Francisco V"],"funding":["Research Executive Agency of the European Union","Instituto de Salud Carlos III (ISCIII) and co-funded by European Social Fund Plus (ESF+)","Xunta de Galicia","Spanish Ministry of Science and Innovation","European Regional Development Fund (FEDER) and the Generalitat Valenciana","ISCIII and FEDER","Xunta de Galicia, Consellería de Educación, Universidade e Formación Profesional and Consellería de Economía, Emprego e Industria (GAIN)"],"pagination":["1237"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9405285"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(8)"],"pubmed_abstract":["Non-alcoholic fatty liver disease (NAFLD) has become the major cause of chronic hepatic illness and the leading indication for liver transplantation in the future decades. NAFLD is also commonly associated with other high-incident non-communicable diseases, such as cardiovascular complications, type 2 diabetes, and chronic kidney disease. Aggravating the socio-economic impact of this complex pathology, routinely feasible diagnostic methodologies and effective drugs for NAFLD management are unavailable. The pathophysiology of NAFLD, recently defined as metabolic associated fatty liver disease (MAFLD), is correlated with abnormal adipose tissue-liver axis communication because obesity-associated white adipose tissue (WAT) inflammation and metabolic dysfunction prompt hepatic insulin resistan"],"journal":["Biology"],"pubmed_title":["Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?"],"pmcid":["PMC9405285"],"funding_grant_id":["GPC IN607B-2019/10","PID2020-120336RB-I00","Miguel Servet Programme contract to Vera Francisco (CP21/00025)","PI20/00902","RICORS Programme, RD21/0002/0025","-RISE Action of the H2020 Programme (project number 734899)","PROMETEO/2019/032","research-staff contract (Instituto de Salud Carlos III (ISCIII) /SERGAS)"],"pubmed_authors":["Marques P","Ait Eldjoudi D","Sanz MJ","Francisco V","Gualillo O","Real JT","Capuozzo M"],"additional_accession":[]},"is_claimable":false,"name":"Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?","description":"Non-alcoholic fatty liver disease (NAFLD) has become the major cause of chronic hepatic illness and the leading indication for liver transplantation in the future decades. NAFLD is also commonly associated with other high-incident non-communicable diseases, such as cardiovascular complications, type 2 diabetes, and chronic kidney disease. Aggravating the socio-economic impact of this complex pathology, routinely feasible diagnostic methodologies and effective drugs for NAFLD management are unavailable. The pathophysiology of NAFLD, recently defined as metabolic associated fatty liver disease (MAFLD), is correlated with abnormal adipose tissue-liver axis communication because obesity-associated white adipose tissue (WAT) inflammation and metabolic dysfunction prompt hepatic insulin resistan","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-27T02:38:58.144Z","creation":"2025-02-19T04:38:16.399Z"},"accession":"S-EPMC9405285","cross_references":{"pubmed":["36009862"],"doi":["10.3390/biology11081237"]}}